Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 13/20 | 0.59 |
| ▸ | LPL | P06858 | 12/20 | 0.59 |
| ▸ | CA1 | P00915 | 3/20 | 0.49 |
| ▸ | CA2 | P00918 | 3/20 | 0.49 |
| ▸ | CA9 | Q16790 | 3/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA3 | P07451 | 1/20 | 0.49 |
| ▸ | CA4 | P22748 | 1/20 | 0.49 |
| ▸ | CA6 | P23280 | 1/20 | 0.49 |
| ▸ | CA5A | P35218 | 1/20 | 0.49 |
| ▸ | CA7 | P43166 | 1/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.49 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.49 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
| ▸ | F11 | P03951 | 2/20 | 0.47 |
| ▸ | P4HB | P07237 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.41 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.41 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL228212 | 0.88 | LPL (0.71) | LIPGLPLCA1CA2CA9 | |
| SCHEMBL21125541 | 0.83 | LIPG (0.51) | LIPGLPLCA1CA2CA9 | |
| SCHEMBL24608995 | 0.81 | LIPG (0.83) | LIPGLPLCA1CA2CA9 | |
| SCHEMBL2707320 | 0.81 | LIPG (0.83) | LIPGLPLCA1CA2CA9 | |
| SCHEMBL12648067 | 0.81 | LPL (0.53) | LIPGLPLCA1CA2CA9 | |
| SCHEMBL64653 | 0.79 | LPL (0.61) | LIPGLPLCA1CA2CA9 | |
| SCHEMBL55445 | 0.77 | LPL (0.59) | LIPGLPLCA1CA2CA9 | |
| SCHEMBL12548009 | 0.77 | LIPG (0.59) | LIPGLPLCA1CA2CA9 | |
| SCHEMBL10323 | 0.77 | LPL (0.88) | LIPGLPLCA1CA2CA9 | |
| SCHEMBL171682 | 0.77 | LPL (0.59) | LIPGLPLCA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114621146-A | Compounds useful as kinase inhibitors | 洛克索肿瘤学股份有限公司 | 2022-06-14 | — | — | CN | disclosed |
| US-20180221342-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-08-09 | — | — | US | disclosed |
| WO-2017023631-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-02-09 | — | — | WO | disclosed |
| EP-1994004-B1 | 1,4-DISUBSTITUTED 3-CYANO-PYRIDONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS | JANSSEN PHARMACEUTICALS INC (US) | 2012-08-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180221342-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, MAVS, EIF2AK2 | LIPG 1919/4885LPL 1413/4885CA1 4815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.